Troikaa Pharma receives DSIR award for R&D efforts
Tuesday, January 27, 2009 16:30 IST Our Bureau, Mumbai
Troikaa Pharmaceuticals Ltd will be conferred with DSIR National Award for R&D efforts in Industry 2008. The company will receive the award for successfully developing through its in house R&D, the world's first painless diclofenac injection marketed as Dynapar AQ injection.
The award will be conferred by the Ministry of Science & Technology, Government of India, on 22nd National Conference on in-house R & D in industry to be organized by DSIR.
Ketan Patel, managing director, Troikaa Pharmaceuticals said, "Our focus has always been to address unmet medical needs through innovative drug delivery. We are glad to receive this award as it highlights our excellent track record of research work on new drug delivery systems & innovations."
Diclofenac injections are routinely used for management of acute pain and inflammation. Dynapar AQ painless injections are the only diclofenac injections in the world that can be administered in the arm muscles.
The novel drug delivery composition and the process of its manufacturing have been patented in 28 countries. In another 71 countries, the process of sealing the patents is in progress.
Troikaa Pharma is fast growing healthcare company based in Ahmedabad that commenced its commercial activities in the year 1984.
Troikaa's state-of-the-art manufacturing facilities are certified by the World Health Organization for following Good Manufacturing Practices and its Quality Management Systems certified by KVQA to follow ISO 9001:2000 standards for manufacturing and supply of Drugs and Pharmaceuticals.